Nothing Special   »   [go: up one dir, main page]

IT1252867B - PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE

Info

Publication number
IT1252867B
IT1252867B ITMI913510A ITMI913510A IT1252867B IT 1252867 B IT1252867 B IT 1252867B IT MI913510 A ITMI913510 A IT MI913510A IT MI913510 A ITMI913510 A IT MI913510A IT 1252867 B IT1252867 B IT 1252867B
Authority
IT
Italy
Prior art keywords
progesterone
compositions containing
pharmaceutical compositions
bioavailability
containing high
Prior art date
Application number
ITMI913510A
Other languages
Italian (it)
Inventor
Sergio Rosini
Fabio Carli
Original Assignee
Gentili Ist Spa
Vectorpharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentili Ist Spa, Vectorpharma Int filed Critical Gentili Ist Spa
Priority to ITMI913510A priority Critical patent/IT1252867B/en
Publication of ITMI913510A0 publication Critical patent/ITMI913510A0/en
Priority to PCT/EP1992/002982 priority patent/WO1993012797A1/en
Priority to AU32578/93A priority patent/AU3257893A/en
Publication of ITMI913510A1 publication Critical patent/ITMI913510A1/en
Application granted granted Critical
Publication of IT1252867B publication Critical patent/IT1252867B/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilità costituite da progesterone supportato su un materiale scelto nel gruppo costituito da ?-ciclodestrina e da polivinilpirrolidone reticolato, unitamente a sostanze eccipienti di usuale impiego nella tecnica farmaceutica, utili nella terapia delle forme di insufficienza di progesterone.Pharmaceutical compositions containing progesterone with high bioavailability consisting of progesterone supported on a material selected from the group consisting of? -Cyclodextrin and cross-linked polyvinylpyrrolidone, together with excipients of usual use in the pharmaceutical technique, useful in the therapy of forms of insufficiency of progesterone.

ITMI913510A 1991-12-31 1991-12-31 PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE IT1252867B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITMI913510A IT1252867B (en) 1991-12-31 1991-12-31 PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE
PCT/EP1992/002982 WO1993012797A1 (en) 1991-12-31 1992-12-23 Pharmaceutical compositions containing natural progesterone having a high biological availability
AU32578/93A AU3257893A (en) 1991-12-31 1992-12-23 Pharmaceutical compositions containing natural progesterone having a high biological availability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI913510A IT1252867B (en) 1991-12-31 1991-12-31 PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE

Publications (3)

Publication Number Publication Date
ITMI913510A0 ITMI913510A0 (en) 1991-12-31
ITMI913510A1 ITMI913510A1 (en) 1993-07-01
IT1252867B true IT1252867B (en) 1995-06-28

Family

ID=11361454

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI913510A IT1252867B (en) 1991-12-31 1991-12-31 PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE

Country Status (3)

Country Link
AU (1) AU3257893A (en)
IT (1) IT1252867B (en)
WO (1) WO1993012797A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652196A1 (en) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogeneous pre-formulations containing steroids for the production of low-dose solid and semi-solid pharmaceutical preparations
IT1296464B1 (en) * 1997-11-19 1999-06-25 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF DRUG-LOADED CROSS-LINKED POLYMER POWDERS AND RELATED PREPARATION PROCESS BY MEANS
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
BR112017027688A2 (en) 2015-06-22 2018-09-04 Lipocine Inc ORAL COMPOSITIONS CONTAINING 17- HYDROXYPROGESTERONE ESTER AND RELATED METHODS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230566B (en) * 1988-10-17 1991-10-28 Vectorpharma Int LITTLE SOLUBLE DRUGS SUPPORTED ON POLYMERIC SUBSTANCES IN A FORM THAT WILL INCREASE THE DISSOLUTION SPEED
IT1241417B (en) * 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS

Also Published As

Publication number Publication date
ITMI913510A1 (en) 1993-07-01
ITMI913510A0 (en) 1991-12-31
WO1993012797A1 (en) 1993-07-08
AU3257893A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
DK0730444T3 (en) Sustained-release preparations for 24-hour release of metoprolol.
DK1036058T3 (en) adamantane
DK1036059T3 (en) adamantane
DE69018647D1 (en) DRUG.
HK1049521A1 (en) High precision orientation alignment and gap control stages for imprint lithography processes
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
NO903001D0 (en) PROCEDURE FOR MANUFACTURING PHARMACEUTICAL PREPARATIONS WITH EXTENDED RELEASE.
NO991405L (en) Coated particle formulation
KR0156686B1 (en) Pharmaceutical composition comprising aryl-substituted rhodanine derivatives
PH31073A (en) Pharmaceutical composition and process for the preparation thereof.
IT1252867B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE
AU3743295A (en) Colchicine derivatives and the therapeutical use thereof
EP0670166A3 (en) Formulations for orally administered pharmaceutical agents.
DE69022957D1 (en) Stretcher.
GB9123353D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
ES2115055T3 (en) 1-PHENYL-2- (2-PIRIDINYL) ETHYLAMINE ENANTIOMERA FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS.
TR199800765T2 (en) A pharmaceutical composition for the treatment of autoimmune diseases
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.
NO894594D0 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING LABDAN DITERPENOID DERIVATIVES AND PYRIMIDO (6.1-A) ISOQUINOLIN-4-ONO DERIVATIVES.
ITRM920535A1 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION THROUGH THE MUCOSES.
NZ237131A (en) 5-substituted 2',3'-dideoxy-3'-fluorouridine derivatives; preparatory processes and pharmaceutical compositions
OA09301A (en) "New oral dosage form improving bioavailability".
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
NZ240927A (en) Dibenz-oxa-thiocinones; preparatory processes, uses, and pharmaceutical compositions
EP0643060A3 (en) Sulfonylbenzyl-substituted benzimidazoles, process for their preparation, and their pharmaceutical use.

Legal Events

Date Code Title Description
0001 Granted